Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 3, 2012, Pages 482-486

  Rizk, Nabil P ^a   Servais, Elliot L ^a   Tang, Laura H ^a   Sima, Camelia S ^a   Gerdes, Hans ^a   Fleisher, Martin ^a   Rusch, Valerie W ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESOTHELIN; SOLUBLE MESOTHELIN RELATED PEPTIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; FEMALE; HUMAN; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; GPI-LINKED PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84859387466     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0993     Document Type: Article

References (24)

1. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31. (Pubitemid 41772961)
2. Wang JS, Canto MI. Predicting Neoplastic Progression in Barrett's Esophagus. Ann Gastroentol Hepatol 2010;1:1-10.
3. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004;127:310-30. (Pubitemid 38962298)
4. Somerville M, Garside R, Pitt M, Stein K. Surveillance of Barrett's oesophagus: is it worthwhile? Eur J Cancer 2008;44:588-99.
5. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40. (Pubitemid 34173814)
6. Downs-Kelly E, Mendelin JE, Bennett AE, Castilla E, Henricks WH, Schoenfield L, et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies. Am J Gastroenterol 2008;103:2333-40; quiz 41.
7. Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-9. (Pubitemid 36750373)
8. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53. (Pubitemid 350262830)
9. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-53. (Pubitemid 43166134)
10. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008;7:286-96. (Pubitemid 351302523)
11. Liebig B, Brabletz T, Staege MS, Wulfanger J, Riemann D, Burdach S, et al. Forced expression of deltaN-TCF-1B in colon cancer derived cell lines is accompanied by the induction of CEACAM5/6 and mesothelin. Cancer Lett 2005;223:159-67. (Pubitemid 40693721)
12. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 2011;17:1181-9.
13. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, et al. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010;28:3316-22.
14. Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott M, Ladanyi M, et al. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med 2010;48:271-8.
15. Ong CA, Lao-Sirieix P, Fitzgerald RC. Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol 2010;16:5669-81.
16. Alvarez H, Rojas PL, Yong KT, Ding H, Xu G, Prasad PN, et al. Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy. Nanomedicine 2008;4:295-301.
17. Fiorentino M, Capizzi E, Loda M. Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am 2010;37:131-41. Table of Contents.
18. Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquee L, Nackaerts K, et al. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: A prospective longitudinal cohort study. J Thorac Oncol 2011;6:889-95.
19. Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009;87:392-8; discussion 8-9.
20. Klaeser B, Nitzsche E, Schuller JC, Koberle D, Widmer L, Balmer-Majno S, et al. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie 2009;32:724-30.
21. McLoughlin JM, Melis M, Siegel EM, Dean EM, Weber JM, Chern J, et al. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer? J Am Coll Surg 2008;206:879-86; discussion 86-7.
22. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152-60; discussion 60.
23. Vallbohmer D, Holscher AH, Dietlein M, Bollschweiler E, Baldus SE, Monig SP, et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009;250:888-94.
24. Sarkaria IS, Rizk NP, Bains MS, Tang LH, Ilson DH, Minsky BI, et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg 2009;249:764-7.